Medical/Pharmaceuticals
BioAgilytix to Purchase Australia-based 360biolabs®
Highly complementary transaction will strengthen company's ability to support bioanalytical services across all stages, development capabilities and geographies DURHAM, N.C., Aug. 16, 2021 /PRNewswire/ -- BioAgilytix Labs, LLC (BioAgilytix), a leading global contract research laboratory focused ...
2021-08-16 18:00
4349
Senhwa Completes Enrollment of a Phase 2 Investigator Initiated Trial of Silmitasertib as Novel Oral Drug for COVID-19
TAIPEI and SAN DIEGO, Aug. 16, 2021 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focused on human efficacy and innovation of first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, today announced that its novel oral drug, Silmita...
2021-08-16 15:29
2173
Introducing ProXmask(TM): Antiviral Face Mask as Better Alternative to Double-Masking and Capable of Inactivate SARS-CoV-2
KUALA LUMPUR, Malaysia, Aug. 16, 2021 /PRNewswire/ -- ProXmask™ is the first antiviral face mask mass-produced in theAsia Pacific by Prolexus Group. The antiviral face mask created by Prolexus Group is a remarkable example of conventional OEM (original equipment manufacturer) for globally renowne...
2021-08-16 15:21
3821
Occlutech granted important conditional FDA approval for PFO Study (OCCLUFLEX) in the U.S.
SCHAFFHAUSEN, Switzerland, Aug. 16, 2021 /PRNewswire/ -- Occlutech Holding AG ("Occlutech"), one of the world´s leading providers of minimally invasive structural heart disease devices, announces the conditional U.S. Food and Drug Administration ("FDA") approval of its Investigational Device Exem...
2021-08-16 14:00
2797
Sino Biological Announces Successful Closing of 4.98 Billion RMB Public Offering and Listing on the Shenzhen ChiNext Stock Exchange
BEIJING, Aug. 16, 2021 /PRNewswire/ -- Sino Biological, Inc. ("Sino Biological" or the "Company"), a biotechnology company which provides biological research reagents and related technical contract research services, announced a successful listing on the Shenzhen Stock Exchange subsidiary ChiNext...
2021-08-16 13:12
6252
GeneQuantum announces a key leadership appointment
SUZHOU, China, Aug. 15, 2021 /PRNewswire/ -- GeneQuantum Healthcare, an industry leading biopharmacetucial company dedicated to next generation bioconjugate drugs through innovative intelligent ligase-dependent conjugation (iLDC) technology platform, announced a key appointment to further strengt...
2021-08-16 10:00
1744
InnoCare Announces First Subject Dosed in Clinical Trial of ICP-332
BEIJING, Aug. 15, 2021 /PRNewswire/ -- InnoCare (HKEX: 09969), a leading biopharmaceutical company focusing on drug innovation for cancer and autoimmune diseases, announced today the first subject dosed in clinical trial of novel TYK2 (Tyrosine Kinase 2) inhibitor ICP-332 inChina. InnoCare disc...
2021-08-16 09:32
8335
InxMed's IN10018 Receives U.S. FDA Fast Track Designation for the Treatment of Platinum-resistant Ovarian Cancer
NANJING, China, Aug. 15, 2021 /PRNewswire/ -- InxMed (Nanjing) Co., Ltd. ("InxMed" or "Company"), a clinical stage biotech company dedicated to developing innovative, individualized medicines with international impact, announced today the U.S. Food and Drug Administration (FDA) has granted Fas...
2021-08-16 09:31
1962
Arctic Vision Announces Expansion of License Territory for Suprachoroidal Space Injection Therapy ARVN001 to Include ASEAN Countries and India
SHANGHAI, Aug. 15, 2021 /PRNewswire/ -- Arctic Vision, a China-based biotech company focused on innovative ophthalmic therapies, announced today the entering of an amendment to the exclusive license agreement with its partner Clearside Biomedical, Inc. (Nasdaq: CLSD) ("Clearside"), to expand the ...
2021-08-16 08:00
8333
Innovent Announces Sintilimab in Combination with Chemotherapy Meets the Primary Endpoint of Overall Survival in the Phase 3 ORIENT-16 Study for the First-Line Treatment of Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
SAN FRANCISCO and SUZHOU, China, Aug. 16, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major di...
2021-08-16 08:00
7079
RenalSense Announces Distribution Agreement in Mainland China with Gloryway
JERUSALEM and BEIJING, Aug. 16, 2021 /PRNewswire/ -- RenalSense™, an Israeli company specializing in real-time renal diagnostics, today announced a distribution agreement with Gloryway, a leading distributor in mainlandChina of medical devices in anesthesia, airway management, temperature managem...
2021-08-16 08:00
3516
Senhwa Signs Agreement with Taiwan's CDE for COVID-19 Program Guiding Development of Silmitasertib
TAIPEI and SAN DIEGO, Aug. 13, 2021 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focused on first-in-class therapeutics for oncology, rare diseases, and coronaviruses, today announced that its novel oral drug, Silmitasertib, has been included inTaiwan's Center...
2021-08-14 10:48
3536
China Pharma Holdings, Inc. Reports Second Quarter 2021 Financial Results
HAIKOU, China, Aug. 13, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based inChina, today announced the financial results for the qu...
2021-08-14 04:30
17872
A3P Biomedical AB: Fast track publication of the STHLM3 MRI trial in The Lancet Oncology
STOCKHOLM, Aug. 13, 2021 /PRNewswire/ -- A3P Biomedical AB today announced that the publication of the STHLM3 MRI trial including 12,750 men has been fast tracked and is now published in the renowned peer-reviewed scientific publication The Lancet Oncology1. Results from the STHLM3 MRI trial, p...
2021-08-13 12:22
1948
TOT BIOPHARM Anounces 2021 Interim Results
Revenue Surges 78% to RMB23.13 million CDMO Business Achieves Leapfrog Breakthrough Two Products Approved for Launch Smooth Progress of Various Core Anti-tumor Drugs Clinical Trials To Allocate Resources to Boost Innovative ADC Drugs HONG KONG and SUZHOU, China, Aug. 13, 2021 /PRNewswire/ -- TOT B...
2021-08-13 10:59
20666
MedAlliance announces Completion of Enrolment in PRISTINE Clinical Trial with SELUTION SLR™ Sirolimus Drug Eluting Balloon
NYON, Switzerland, Aug. 13, 2021 /PRNewswire/ -- MedAlliance has announced completion of patient enrolment in the PRISTINE clinical trial with SELUTION SLR™ 018 DEB (drug-eluting balloon) for the treatment of patients with Below-the-Knee (BTK) disease. SELUTION SLR is the first DEB to be awarded ...
2021-08-13 08:00
4898
Diabetes treatment lowers PromarkerD risk score for diabetic kidney disease
BRISBANE, Australia, Aug. 12, 2021 /PRNewswire/ -- Treatment with diabetes drug canagliflozin lowers the PromarkerD risk score for developing diabetic kidney disease in patients with type 2 diabetes, latest research suggests. In a study presented at the Australasian Diabetes Congress today, resea...
2021-08-12 21:30
2819
Fujifilm Introduces its AI-powered Product for Chest X-ray in Japan, in Collaboration with Lunit
SEOUL, South Korea, Aug. 12, 2021 /PRNewswire/ -- Fujifilm Corporation, a global medical imaging device provider, today announced its AI-powered product for analyzing chest X-ray 'CXR-AID' will be commercially available acrossJapan. CXR-AID is designed to better detect major abnormal findings ...
2021-08-12 20:38
2776
Zhongchao Inc. Builds A Patient DOT Management System
SHANGHAI, China, Aug. 12, 2021 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a healthcare services company offering patient management, online healthcare information, professional training and educational services, today announced that its subsidiary Shanghai Zho...
2021-08-12 20:30
4955
WuXi AppTec Reports Strong 2021 Interim Results
* Revenue Up 45.7% Year-Over-Year to RMB10,537 Million * Net Profit Attributable to Owners of the Company Up 55.8% Year-Over-Year to RMB2,675 Million * Diluted EPS Up 46.8% Year-Over-Year to RMB0.91 * Adjusted Non-IFRS[1] Net Profit Attributable to Owners of the Company Up 67.8% Year-Over-...
2021-08-12 17:52
3924
Week's Top Stories
Most Reposted
Visa and Trip.com Group Ink Strategic Collaboration, Enabling Consumers to Chase Their Passions Through Travel
[Picked up by 309 media titles]
2026-05-19 18:10
Two-day Global Prosperity Summit 2026 officially opens
[Picked up by 308 media titles]
2026-05-19 23:59
Two‑day Global Prosperity Summit 2026 concludes successfully
[Picked up by 303 media titles]
2026-05-21 22:13
Hyundai Motor Group to Pioneer Hong Kong's Hydrogen Economy, Accelerating Asia-Pacific Expansion
[Picked up by 290 media titles]
2026-05-18 15:30
Autonomous AI marketing platform Protaigé launches with Maia, the world's first AI Account Director that operates within the flow of work
[Picked up by 281 media titles]
2026-05-20 09:15Most Read
NYSE Content Update: Lincoln International Pops by 13% in First Day of Trade
2026-05-21 21:04
7189
Scienjoy Holding Corporation Reports Unaudited First Quarter 2026 Financial Results
2026-05-21 20:30
7087
/C O R R E C T I O N -- The American Chamber of Commerce in Singapore (AmChamSG)/
2026-05-21 12:14
6428
NYSE Content Update: Armada Raises $230 Million, Boosts Valuation to $2 Billion
2026-05-19 21:02
6353
